Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462540 · ClinicalTrials.gov registry record · Phase 3
A Crossover Study in the Treatment of Patients With COPD
A Phase 3 study, sponsored by Dey.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00462540 is a Phase 3 study that has completed, run by Dey. The registered enrollment target is 100 participants.
The verdict
NCT00462540, a Phase 3 study, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol \[2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID\], and to Compare the preference/compliance of BID nebulization to QID use of MDI
Interventions
- DRUG Formoterol Fumurate inhalation solution 20 mcg
- DRUG Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-05 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00462540
The ClinicalTrials.gov registry entry for NCT00462540 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dey, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Formoterol Fumurate inhalation solution 20 mcg is the first listed.
NCT00462540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00462540 about?
NCT00462540 is a clinical study titled "A Crossover Study in the Treatment of Patients With COPD". The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol \[2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID\], and to Compare the preference/complianc...
What is the current status of trial NCT00462540?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2007-05. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00462540?
The interventions under investigation include: Formoterol Fumurate inhalation solution 20 mcg (DRUG), Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg (DRUG).
Who is sponsoring clinical trial NCT00462540?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.